Chemomab Therapeutics Ltd... (CMMB)
2.00
0.10 (5.26%)
At close: Jan 15, 2025, 10:26 AM
Company Description
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis.
The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021.
Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Chemomab Therapeutics Ltd.
| Country | IL |
| IPO Date | Feb 12, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Dr. Adi Mor George Ph.D. |
Contact Details
Address: Building 7 Tel Aviv, IL | |
| Website | https://www.chemomab.com |
Stock Details
| Ticker Symbol | CMMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534248 |
| CUSIP Number | 03280X102 |
| ISIN Number | US16385C1045 |
| Employer ID | 81-3676773 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, Chief Executive Officer & Executive Director |
| Sigal Fattal CPA, M.B.A. | Chief Financial Officer |
| Barbara Lindheim | Consulting Vice President of Investor & Public Relations, Strategic Communications |
| Dr. Matthew B. Frankel M.B.A., M.D. | Chief Medical Officer & Vice President of Drug Development |
| Jack Lawler | Senior Vice President of Global Clinical Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 02, 2024 | POS AM | Filing |
| Nov 29, 2024 | SC 13D/A | [Amend] Filing |
| Nov 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 18, 2024 | 6-K | Filing |
| Nov 15, 2024 | 424B5 | Filing |
| Nov 14, 2024 | 6-K | Filing |
| Oct 11, 2024 | 6-K | Filing |
| Sep 16, 2024 | SC 13D/A | [Amend] Filing |
| Sep 09, 2024 | 424B3 | Filing |
| Aug 23, 2024 | F-3 | Filing |